MetaboGen: MetaboGen reaches development goal - first product ready for safety study

BioGaia's subsidiary MetaboGen has reached an important development goal. The first version of its next generation probiotic product is now ready to go in to a safety study. MetaboGen focuses its research on the microbiome and on finding breakthrough opportunities that can be developed into novel therapeutics and the next generation of probiotics. A number of development programs are now being pursued by the company. Management of metabolic disease Two strains, Faecalibacterium prausnitzii (DSM 32379) and Desulfovibrio piger (DSM 32187), derived from the human gut microbiome, have been